Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for VTRS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 1.410B
March 31, 2026 2.261B
December 31, 2025 1.454B
September 30, 2025 1.108B
June 30, 2025 667.60M
March 31, 2025 850.80M
December 31, 2024 829.60M
September 30, 2024 1.975B
June 30, 2024 1.009B
March 31, 2024 1.107B
December 31, 2023 1.080B
September 30, 2023 1.392B
June 30, 2023 713.60M
March 31, 2023 587.60M
December 31, 2022 1.338B
September 30, 2022 981.50M
June 30, 2022 947.70M
March 31, 2022 1.040B
December 31, 2021 935.00M
September 30, 2021 849.40M
June 30, 2021 767.20M
March 31, 2021 898.50M
December 31, 2020 934.90M
September 30, 2020 667.10M
June 30, 2020 324.70M
Date Value
March 31, 2020 587.90M
December 31, 2019 600.20M
September 30, 2019 374.40M
June 30, 2019 212.70M
March 31, 2019 230.90M
December 31, 2018 480.60M
September 30, 2018 503.10M
June 30, 2018 384.20M
March 31, 2018 445.10M
December 31, 2017 569.40M
September 30, 2017 953.60M
June 30, 2017 967.60M
March 31, 2017 859.60M
December 31, 2016 1.322B
September 30, 2016 1.413B
June 30, 2016 6.518B
March 31, 2016 1.306B
December 31, 2015 1.343B
September 30, 2015 693.50M
June 30, 2015 581.70M
March 31, 2015 408.10M
December 31, 2014 359.60M
September 30, 2014 405.20M
June 30, 2014 325.30M
March 31, 2014 374.50M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Pfizer Inc. 11.70B
Eli Lilly & Co. 8.95B
Merck & Co., Inc. 7.182B
Bristol Myers Squibb Co. 11.07B
Johnson & Johnson 20.76B